Previous 10 | Next 10 |
PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PR Newswire - 2022 recipients include patient advocacy organizations from Brazil , Greece , Turkey , and the U.K. - SOUTH PLAINFIELD, N.J....
Shares have lost 20% of their value since the initial public offering in February of last year. The company is well-positioned as a "picks and shovels" play to pharmaceutical partners addressing neurological indications. Much of the management team previously served at Philips and...
PTC Therapeutics (PTCT) Q2 2022 Earnings Conference Call August 4, 2022 16:30 ET Company Participants Kylie O'Keefe - Senior Vice President, Head of Global Commercial & Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating ...
PTC Therapeutics ( NASDAQ: PTCT ) shows a 42% growth in revenue to $166M. Revenue includes net product revenue across the commercial portfolio of $143.7M vs. $103.1M last year. Royalty revenue of $21.8M vs. $13.6M. Bifurcating: Translarna net product revenues were $77M...
PTC Therapeutics press release ( NASDAQ: PTCT ): Q2 GAAP EPS of -$2.13 misses by $0.76 . Revenue of $166M (+42.2% Y/Y) beats by $3.47M . FY22 revenues expected to be between $700M and $750M (vs. consensus of $718.20M) For further details see: PTC Ther...
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results PR Newswire - Total revenue of $166 million , representing 42% year-over-year growth – - Upstaza™ gene therapy granted marketing authorization by European Comm...
Shares of PTC Therapeutics ( PTCT ) are up ~6% in Monday afternoon trading ahead of the company Q2 2022 earnings call after the closing bell on August 4. The company also hit a 52-week highof $47.57. The Q2 revenue consensus estimate is $162.53M, while the normalized E...
The following slide deck was published by PTC Therapeutics, Inc. in conjunction with this event. For further details see: PTC Therapeutics Investor Presentation - Slideshow
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , July 21, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast confere...
The European Commission (EC) approved PTC Therapeutics' ( NASDAQ: PTCT ) one-time gene replacement therapy Upstaza to treat aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults. The company said Upstaza (eladocagene exuparvovec) i...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....